Short answer
Jade Biosciences, Inc. (JBIO) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Quarterly results covered period ended June 30, 2026.
Jade Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Quarterly results covered period ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains financial results and management commentary
- Results announcement dated August 10, 2026
Item EX-99.1 · Exhibit EX-99.1
- Positive interim JADE101 data: approximately 70% mean IgA reduction after one 700 mg dose, supporting potential every-12-week maintenance dosing
- JADE101 Phase 2 underway with interim data expected in 2027; Phase 3 planned for first half of 2027 pending FDA feedback
- Cash, cash equivalents and investments of $461.2 million support projected operations into fourth quarter 2028 after $172.5 million public offering
- Q2 R&D expense increased to $50.1 million from $22.5 million; net loss widened to $55.8 million from $32.1 million
- JADE201 rheumatoid arthritis dosing began; JADE301 Phase 1 initiation expected in fourth quarter 2026, expanding pipeline catalysts into 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Jade Biosciences, Inc. 8-K filings
Get the next JBIO 8-K as it lands
Follow JBIO for push alerts, or ask the research agent what this filing means.